ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,164.12
-0.19%
Dow Jones
39,118.86
-0.12%
Gold vs US Dollar
2,326.73
0.00%
Brent Oil
84.85
0.00%
Bitcoin
61,487.19
0.98%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Janux Therapeutics Inc (JANX)

  7. Janux Therapeutics Inc (JANX) News

Janux Therapeutics (JANX)

Janux Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:JANX
DateTimeSourceHeadlineSymbolCompany
17/06/202422:02Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:JANXJanux Therapeutics Inc
04/06/202400:02Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:JANXJanux Therapeutics Inc
04/06/202400:02Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:JANXJanux Therapeutics Inc
03/06/202423:48Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:JANXJanux Therapeutics Inc
08/05/202414:13Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:JANXJanux Therapeutics Inc
07/05/202421:01Business WireJanux Therapeutics Reports First Quarter 2024 Financial Results and Business HighlightsNASDAQ:JANXJanux Therapeutics Inc
08/03/202421:47Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:JANXJanux Therapeutics Inc
08/03/202421:23Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:JANXJanux Therapeutics Inc
08/03/202421:11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:JANXJanux Therapeutics Inc
08/03/202421:01Business WireJanux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business HighlightsNASDAQ:JANXJanux Therapeutics Inc
29/02/202422:30Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:JANXJanux Therapeutics Inc
29/02/202422:11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:JANXJanux Therapeutics Inc
29/02/202406:22Business WireJanux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded WarrantsNASDAQ:JANXJanux Therapeutics Inc
29/02/202402:55Edgar (US Regulatory)Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectusesNASDAQ:JANXJanux Therapeutics Inc
28/02/202422:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:JANXJanux Therapeutics Inc
28/02/202402:50Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:JANXJanux Therapeutics Inc
27/02/202422:23Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:JANXJanux Therapeutics Inc
27/02/202422:00Business WireJanux Therapeutics Announces Proposed Public Offering of Common StockNASDAQ:JANXJanux Therapeutics Inc
26/02/202421:05Business WireJanux Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for PSMAxCD3-TRACTr JANX007 in mCRPC and EGFRxCD3-TRACTr JANX008 in Solid TumorsNASDAQ:JANXJanux Therapeutics Inc
20/02/202413:00Business WireJanux Therapeutics to Host Virtual Event Discussing Updated Clinical Data for PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008NASDAQ:JANXJanux Therapeutics Inc
09/02/202421:31Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:JANXJanux Therapeutics Inc
01/02/202421:15Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:JANXJanux Therapeutics Inc
08/01/202414:00Business WireJanux Therapeutics Promotes Co-Founder Tommy DiRaimondo, Ph.D. to Chief Scientific OfficerNASDAQ:JANXJanux Therapeutics Inc
03/01/202421:54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:JANXJanux Therapeutics Inc
03/01/202421:53Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:JANXJanux Therapeutics Inc
03/01/202421:50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:JANXJanux Therapeutics Inc
03/01/202421:49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:JANXJanux Therapeutics Inc
03/01/202421:47Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:JANXJanux Therapeutics Inc
03/01/202421:45Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:JANXJanux Therapeutics Inc
07/11/202321:19Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:JANXJanux Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:JANX

Your Recent History

LSE
ZX00
Stan.ch.bk. 26
HITB
FACEBTC
Faceter
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved